Op0139 Efficacy and Safety of Abbv-599 High Dose (elsubrutinib 60 Mg and Upadacitinib 30 Mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: a Phase 2, Double-blind, Placebo-controlled Trial
Year: 2023
Type: conference-abstract
Source: Annals of the Rheumatic Diseases
Authors: J.T. Merrill, Y. Tanaka, D. D'cruz, K. Vila, D. Siri, X. Zeng, K. D'silva, L. Cheng, T. Sornasse, T. Doan, D. Kruzikas, A. Friedman
Institutions: Oklahoma Medical Research Foundation, University of Occupational and Environmental Health Japan, Hospital of the University of Occupational and Environmental Health, Guy's Hospital, King's College London, Chinese Academy of Medical Sciences & Peking Union Medical College, AbbVie (United States)
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4379522435